T-cell exhaustion
T cells that see their target for weeks on end without winning gradually shut down: they raise a set of brakes (PD-1, LAG-3, TIM-3, TIGIT), lose their ability to kill, and eventually lock this state into their DNA. Checkpoint drugs rescue the ones that are only partly exhausted; the terminally exhausted are beyond reach.
Chronic TCR stimulation with insufficient help drives a stepwise programme: TCF1+ progenitor-exhausted cells (stem-like, lymph-node and tertiary-lymphoid-structure resident, PD-1 intermediate) self-renew and give rise to transitory effector-like cells and then terminally exhausted cells (PD-1 high, TIM-3, CD39, CD101) with poor IL-2/TNF/IFN-γ production, driven by NFAT without AP-1, TOX and NR4A, and fixed by DNMT3A-dependent de novo methylation ('epigenetic scarring'). PD-1 blockade expands the progenitor pool and its transitory progeny rather than reviving terminal cells; response correlates with the size of the TCF1+ reservoir and with CD28 co-stimulation (PD-1 dephosphorylates CD28). Co-inhibitory receptors partition: LAG-3 (MHC-II, FGL1) blocked by relatlimab; TIGIT (CD155) by tiragolumab (mixed phase 3 results); TIM-3 (galectin-9, CEACAM1) by sabatolimab. CAR-T cells exhaust the same way (CD8 CAR-T with c-Jun overexpression or TET2 loss resist it); interval rests and PD-1 knockout are engineering countermeasures.
In one picture
A soldier posted at a wall for months with no relief. First tired, then unwilling to fire, finally unable to, and the last stage is written into their habits so deeply that no order can undo it. Checkpoint inhibitors work on the tired, not the broken.
Diagram
top- Anti-PD-1/PD-L1; combinations with anti-LAG-3 (relatlimab-nivolumab, fianlimab) and anti-TIGIT (tiragolumab, mixed results)
- Earlier use (neoadjuvant) when the TCF1+ reservoir is larger; IL-2 variants and IL-15 superagonists to expand progenitors
- CAR-T engineering: c-Jun overexpression, TET2/DNMT3A editing, transient rest, PD-1 knockout
- Epigenetic drugs to reverse scarring (preclinical)
Pages like this
not linked directly; found by shared links- PathwayNK-cell recognition: missing self & stress ligands
Shares Nogapendekin alfa inbakicept, TIGIT, Tiragolumab, Hallmark: avoiding immune destruction and the tags mechanism, mechanics-atlas.
- PathwayMismatch repair & microsatellite instability
Shares Antigen presentation & immune editing, CTLA-4, PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1 and the tags mechanism, mechanics-atlas.
- PathwayCold tumours: immune deserts and exclusion
Shares Tumour-infiltrating lymphocytes (TILs), The cancer-immunity cycle, Hot vs cold tumours, PD-L1 and the tags mechanism, mechanics-atlas.
- PathwayNutrient competition & metabolic immunosuppression
Shares Armoured, logic-gated & next-gen CARs, Hot vs cold tumours, PD-1, Pembrolizumab and the tags mechanism, mechanics-atlas.
- PathwayExtrinsic apoptosis (death receptors)
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-1, CAR-T cell therapy, Immune checkpoint inhibitors and the tags mechanism, mechanics-atlas.
- PathwayOncogenic viruses
Shares Antigen presentation & immune editing, PD-L1, PD-1, Pembrolizumab and the tags mechanism, mechanics-atlas.
- PathwayComplement in cancer
Shares CD19, PD-1, Immune checkpoint inhibitors and the tags mechanism, mechanics-atlas.
- PathwayResistance routes: how a blocked pathway comes back
Shares Antigen presentation & immune editing, CD19, CAR-T cell therapy and the tags mechanism, mechanics-atlas.